The goal of this in vitro study was to examine the effect of the alpha-2 adrenoceptor agonist dexmedetomidine on phenylephrine (alpha-1 adrenoceptor agonist)-induced contraction in isolated rat aortae and to elucidate the associated cellular mechanisms, with a particular focus on alpha-1 adrenoceptor antagonism. Dexmedetomidine dose-response curves were generated in isolated endothelium-intact and endothelium-denuded rat aortae precontracted with phenylephrine or 5-hydroxytryptamine. Endothelium-denuded aortic rings were pretreated with either dexmedetomidine or the reversible alpha-1 adrenoceptor antagonist phentolamine, followed by post-treatment with the irreversible alpha-1 adrenoceptor blocker phenoxybenzamine. Control rings were treated with phenoxybenzamine alone. All rings were repeatedly washed with Krebs solution to remove all pretreatment drugs, including phenoxybenzamine, phentolamine and dexmedetomidine. Phenylephrine dose-response curves were then generated. The effect of rauwolscine on the dexmedetomidine-mediated change in phenylephrine-induced endothelial nitric oxide synthase (eNOS) phosphorylation in human umbilical vein endothelial cells was examined using western blotting. The magnitude of the dexmedetomidine-mediated inhibition of phenylephrine-induced contraction was higher in endothelium-intact aortae than in endothelium-denuded aortae or endothelium-intact aortae treated with N ω -nitro-L-arginine methyl ester. However, dexmedetomidine did not significantly alter 5-hydroxytryptamine-induced contraction. In further experiments, prazosin attenuated dexmedetomidine-induced contraction. Additionally, pretreatment with either dexmedetomidine plus phenoxybenzamine or phentolamine plus phenoxybenzamine produced greater phenylephrine-induced contraction than phenoxybenzamine alone, suggesting that dexmedetomidine protects aortae from the alpha-1 adrenoceptor blockade induced by phenoxybenzamine. Rauwolscine attenuated the dexmedetomidine-mediated enhancement of phenylephrine-induced eNOS phosphorylation. Taken together, these results suggest that dexmedetomidine attenuates phenylephrine-induced contractions via alpha-1 adrenoceptor blockade and endothelial nitric oxide release in the isolated rat aorta.
Introduction
The highly selective alpha-2 adrenoceptor agonist dexmedetomidine is widely used for sedation in perioperative periods [1, 2] . Intravenous administration of dexmedetomidine produces transient hypertension followed by hypotension, due to alpha-2 adrenoceptor-mediated vasoconstriction and a central sympatholytic effect, respectively [1] [2] [3] . The hypotension caused by dexmedetomidine infusion during various procedures requires a large amount of phenylephrine [4] [5] [6] . Furthermore, dexmedetomidine attenuates the contraction induced by the alpha-1 adrenoceptor agonist phenylephrine in isolated vessels [7, 8] . In addition, it has been reported that dexmedetomidine shows low affinity for the alpha-1 adrenoceptor [9, 10] . These previous reports suggest that high doses of dexmedetomidine induce competitive inhibition at the alpha-1 adrenoceptor via the intrinsic low affinity of dexmedetomidine for the alpha-1 adrenoceptor [7] [8] [9] [10] . The vasoconstriction induced by dexmedetomidine is attenuated by endothelial nitric oxide in isolated endothelium-intact rat aortae [11] . However, the detailed cellular mechanism responsible for the dexmedetomidinemediated inhibition of alpha-1 adrenoceptor-induced contraction remains unknown. Therefore, the goal of this in vitro study was to examine the effect of dexmedetomidine on phenylephrine-induced contraction in isolated rat aorta and to elucidate the associated cellular mechanism, with a particular focus on the antagonistic effects on the alpha-1 adrenoceptor. We tested the hypothesis that dexmedetomidine attenuates phenylephrine-induced contraction via both inhibition of the alpha-1 adrenoceptor and activation of endothelial nitric oxide release.
Materials and Methods
All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee of Gyeongsang National University and were performed in accordance with the Guide for the Care and Use of Laboratory Animals as described previously [12] .
Preparation of aortic rings for tension measurements
Aortic rings were prepared for tension measurements as described previously [12] [13] [14] . Male Sprague-Dawley rats weighing 250-300 g were anesthetized via intramuscular injection of Zoletil 50 (15 mg/kg, Virbac Laboratories, Carros, France). The descending thoracic aorta was then dissected free. The surrounding connective tissue and fat were removed under a microscope, and the vessel was bathed in Krebs solution with the following composition (mM): 118 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2.4 CaCl2, 25 NaHCO3, and 11 glucose. The aorta was then cut into 2.5-mm rings, which were suspended on Grass isometric transducers (FT-03, Grass Instrument, Quincy, MA, USA) under 3.0-g resting tension in a 10-mL Krebs bath at 37°C and continuously aerated with 95% O2 and 5% CO2 to maintain pH values within 7.35-7.45. The rings were equilibrated at a resting tension of 3.0 g for 120 min, during which the bathing solution was changed every 40 min. Care was taken not to damage the endothelium. In some aortic rings, the endothelium was intentionally removed by inserting a 25-gauge needle tip into the lumen of the ring and gently rolling the ring for a few seconds. Once the phenylephrine (10 −7 M)-induced contraction had stabilized, acetylcholine (10 −5 M) was added to assess endothelial integrity. Endothelial integrity was confirmed by the observation of more than 75% relaxation induced by acetylcholine. Once the phenylephrine (10 -8 M)-induced contraction was sustained in the endothelium-denuded rat aorta, acetylcholine was added to assess endothelial denudation; aortic rings showing lees than 20% relaxation induced by acetylcholine were regarded as endothelium-denuded aortic rings in the current experiment. The rings were then rinsed with fresh Krebs solution to restore the resting tension. Next, the contraction induced by isotonic 60 mM KCl was measured, and the magnitude of isotonic 60 mM KCl-induced contraction was used as the reference value (100%) for concentration-response curves induced by phenylephrine [13] . After washing out the KCl from the organ bath with fresh Krebs solution and reaching the baseline resting tension, the main experiments were performed as described in the experimental protocols.
Experimental protocols
We investigated the dexmedetomidine concentration (10 -9 to 10 -6 M)-response curves in isolated endothelium-intact aortae that were either precontracted with phenylephrine (10 -6 M) or pretreated with the nitric oxide synthase inhibitor N ω -nitro-L-arginine methyl ester (L-NAME: 10 −4 M) and precontracted with phenylephrine (10 -6 M) as well as endothelium-denuded aortae pretreated with L-NAME (10 −4 M) and precontracted with phenylephrine (10 -7 M). We regarded isolated rat aortae showing less than 20% acetylcholine-induced relaxation as endothelium-denuded aortae in the current experiment, and endothelial nitric oxide attenuates dexmedetomidine-induced contraction [11] . As the residual endothelium of the endothelium-denuded aorta may affect dexmedetomidine concentration-response curves, endotheliumdenuded aortae were pretreated with 10 −4 M L-NAME for 15 min before the addition of phenylephrine. After phenylephrine had produced a stable and sustained contraction in the isolated rat aorta, dexmedetomidine was cumulatively added to generate dexmedetomidine concentration-response curves.
An alpha-1 adrenoceptor protection experiment was performed to determine whether the dexmedetomidine-mediated inhibition of vasoconstriction induced by the alpha-1 adrenoceptor agonist phenylephrine involves alpha-1 adrenoceptor blockade [15, 16] . Endothelium-denuded rat aortae were pretreated with either dexmedetomidine (3 × 10 -7 , or 10 -6 M) or the reversible alpha-1 adrenoceptor antagonist phentolamine (10 -6 M) for 20 min, followed by post-treatment with the irreversible alpha-1 adrenoceptor antagonist phenoxybenzamine (5 × 10 -8 M) for another 20 min. Control rings were treated with phenoxybenzamine (5 × 10 -8 M) alone for 20 min. All rings were repeatedly washed with fresh Krebs solution every 5 min for 60 min to remove all of the pretreatment drugs, including phenoxybenzamine, dexmedetomidine and phentolamine, and to restore the baseline resting tension. Then, phenylephrine concentration (10 -9 to 10 -5 M)-response curves were generated in the endothelium-denuded washed aorta pretreated with L-NAME (10 −4 M).
We investigated the effect of the cumulative addition of dexmedetomidine on the contraction induced by phenylephrine (10 -7 M) or 5-hydroxytryptamine (3 × 10 -6 M) in an isolated L-NAME (10 −4 M)-pretreated endothelium-denuded rat aorta to determine whether the inhibitory effect of dexmedetomidine on phenylephrine-induced contraction is specifically associated with inhibitory effects on the alpha-1 adrenoceptor. After phenylephrine or 5-hydroxytryptamine had produced a sustained and stable contraction in the endothelium-denuded rat aorta pretreated with L-NAME (10 -4 M), dexmedetomidine (10 -9 to 10 -6 M) was cumulatively added to generate dexmedetomidine concentration-response curves. In addition, we generated prazosin concentration (10 -10 to 3 × 10 -9 M)-response curves in endothelium-denuded aortae that were pretreated with L-NAME (10 -4 M) and precontracted with dexmedetomidine (10 -6 M).
Cell culture
Human umbilical vein endothelial cells (HUVECs; EA.hy926 cells, American Type Culture Collection, Manassas, VA, USA) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mmol/L L-glutamine, 100 IU/mL penicillin, and 10 μg/mL streptomycin as described previously [12] . The cells were cultured in 100-mm dishes and grown in a humidified 5% CO2 incubator. HUVECs were plated at a density of 10 7 cells per 100-mm dish. The cells were used between passage number 7 and passage number 10.
Western blot analysis
Western blot analysis was performed as previously described [12] . Briefly, cells were lysed in PRO-PREP protein extract solution to isolate the total cell extract. After the extract was centrifuged at 13,000 rpm for 20 min at 4°C, the protein concentration was determined via the Bradford method. Samples containing 30 µg of protein were subjected to 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. The separated proteins were then transferred to polyvinylidene difluoride membranes using the SD Semi-dry Transfer Cell ® system (Bio-Rad, Hercules, CA, USA). These membranes were incubated with primary antibodies (anti-endothelial nitric oxide synthase [eNOS] and anti-phospho-eNOS at Ser 1177 antibodies; Cell Signaling Technology, Beverly, MA, USA) at a 1:500 dilution (4 μg/mL) in 5% skim milk in Tris-buffered saline with Tween 20 overnight at 4°C, and bound antibody was detected with horseradish peroxidase-conjugated anti-rabbit IgG. The membranes were washed and then developed using the Luminol Reagent system (Animal Genetics, Suwon, Korea).
Materials
Phenylephrine, prazosin, phenoxybenzamine, phentolamine, 5-hydroxytryptamine, L-NAME and acetylcholine were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). Dexmedetomidine was donated from Orion Pharma (Turku, Finland). DMEM, FBS, penicillin and streptomycin were obtained from Gibco BRL (Rockville, MD, USA). Phentolamine and phenoxybenzamine were dissolved in ethanol. Unless otherwise stated, we dissolved and diluted all other drugs in distilled water.
Data analysis
Dexmedetomidine concentration-response curves are expressed as the percentage of maximal contraction induced by phenylephrine or 5-hydroxytryptamine. Concentration-response curves induced by phenylephrine are expressed as the percentage of maximal contraction induced by isotonic 60 mM KCl. The effects of phenylephrine, 5-hydroxytyptamine and endothelial denudation on the dexmedetomidine concentration-response curves and the effects of various drugs on the phenylephrine dose-response curves were analyzed through two-way repeated measurement analysis of variance (ANOVA) followed by Bonferroni's post-test. Prazosin concentration-response curves were analyzed using repeated measures ANOVA followed by Bonferroni's post-test. The effects of dexmedetomidine alone or combined treatment with rauwolscine and dexmedetomidine on phenylephrine-induced eNOS phosphorylation in HUVECs were analyzed using one-way ANOVA followed by Bonferroni's post-test. Data are expressed as the mean ± SD. N indicates the number of rats from which descending thoracic aortic rings were derived or the number of isolated rat thoracic aortic rings. P values less than 0.05 were considered statistically significant.
Results
A high dose (10 -7 to 10 -6 M) of dexmedetomidine attenuated phenylephrine-induced contraction ( Fig. 1 ; P < 0.05 versus 10 -9 M dexmedetomidine) in endothelium-intact aortae, endothelium-intact aortae pretreated with L-NAME (10 -4 M) and endothelium-denuded aortae pretreated with L-NAME (10 -4 M). However, the dexmedetomidine (10 -7 to 10 -6 M)-mediated attenuation of phenylephrine-induced contraction was greater in endothelium-intact aortae than in endothelium-intact or endothelium-denuded aortae pretreated with L-NAME ( Fig. 1 ; P < 0.05). Combined treatment with either dexmedetomidine (3 × 10 -7 or 10 -6 M) and phenoxybenzamine (5 × 10 -8 M) or phentolamine (10 -6 M) and phenoxybenzamine (5 × 10 -8 M) enhanced phenylephrine-induced contraction compared with phenoxybenzamine alone (5 × 10 -8 M) ( Fig. 2 ; P < 0.001 at 10 -7 to 10 -5 M phenylephrine). In addition, combined treatment with phentolamine and phenoxybenzamine enhanced phenylephrine-induced contraction compared with dexmedetomidine (10 -6 M) and phenoxybenzamine combined treatment ( Fig. 2 ; P < 0.001 at 10 -8 and 3 × 10 -8 M phenylephrine). Combined treatment with high concentrations of dexmedetomidine (10 -6 M) and phenoxybenzamine enhanced phenylephrine-induced contraction compared with combined treatment with low concentrations of dexmedetomidine (3 × 10 -7 M) and phenoxybenzamine ( Fig. 2 ; P < 0.05 at 3 × 10 -8 to 3 × 10 -7 M phenylephrine). Dexmedetomidine had no effect on 5-hydroxytryptamine-induced contraction in isolated L-NAME-pretreated endothelium-denuded aortae, whereas a high dose (10 -7 to 10 -6 M) of dexmedetomidine attenuated phenylephrine-induced contraction ( Fig.  3A ; P < 0.001 versus 5-hydroxytryptamine). Prazosin (3 × 10 -9 M) attenuated dexmedetomidine-induced contraction ( Fig. 3B ; P < 0.001 versus 10 -6 M dexmedetomidine).
Phenylephrine (10 -8 M) induced eNOS phosphorylation in HUVECs ( Fig. 4 ; P < 0.001 versus the control), and dexmedetomidine (3 × 10 -7 M) enhanced phenylephrine (10 -8 M)-induced eNOS phosphorylation ( Fig. 4 ; P < 0.001 versus phenylephrine alone). Pretreatment with the alpha-2 adrenoceptor antagonist rauwolscine (10 -6 M) attenuated the dexmedetomidine-mediated increase of phenylephrine-induced eNOS phosphorylation ( Fig. 4 ; P < 0.001 versus dexmedetomidine plus phenylephrine). Cumulative dexmedetomidine concentration-response curves for isolated endothelium-intact aortae (N = 5) precontracted with 10 -6 M phenylephrine; endothelium-denuded aorta (N = 5) pretreated with N ω -nitro-L-arginine methyl ester (L-NAME, 10 -4 M) and precontracted with 10 -7 M phenylephrine; or endothelium-intact aorta (N = 7) pretreated with L-NAME (10 -4 M) and precontracted with 10 -6 M phenylephrine. The data are shown as the mean ± SD and expressed as the percentage of maximal contraction induced by phenylephrine. N indicates the number of rats from which descending thoracic aortic rings were derived or the number of isolated rat aortae. *P < 0.05, #P < 0.01 and †P < 0.001 versus endothelium-intact and endothelium-denuded aortae treated with L-NAME.
‡P < 0.05, † †P < 0.01 and §P < 0.001 versus dexmedetomidine (10 -9 M) in each group. 
Discussion
This is the first study to provide laboratory evidence that dexmedetomidine attenuates alpha-1 adrenoceptor-mediated phenylephrine-induced contraction via blockade of the alpha-1 adrenoceptor. Previous studies have shown that fentanyl attenuates alpha-1 adrenoceptor-mediated phenylephrineinduced vasoconstriction [16, 17] . Additionally, dexmedetomidine has been shown to inhibit phenylephrine-induced contraction in the internal mammary and gastroepiploic arteries, suggesting that dexmedetomidine may have an intrinsic affinity for the alpha-1 adrenoceptor [7, 8] . Combined treatment with the reversible alpha-1 adrenoceptor antagonist phentolamine and, subsequently, the irreversible alpha-1 adrenoceptor antagonist phenoxybenzamine enhanced phenylephrine-induced contraction compared with pretreatment with phenoxybenzamine alone (Fig. 2) , suggesting that the reversible occupation of alpha-1 adrenoceptors in vascular smooth muscle by phentolamine appears to spare them from irreversible blockade by phenoxybenzamine, which contributes to enhanced phenylephrine-induced contraction after washout of all of the pretreatment drugs (phenylephrine, dexmedetomidine and phenoxybenzamine) with Krebs solution. In addition, the supraclinical dose (10 -7 to 10 -6 M) of dexmedetomidine used in the current study, which exceeds the clinically relevant concentration (8 × 10 -9 M) of dexmedetomidine for sedation, attenuated alpha-1 adrenoceptor-mediated phenylephrine-induced contraction [18] . Combined pretreatment with dexmedetomidine and phenoxybenzamine enhanced phenylephrine-induced contraction compared with phenoxybenzamine alone (Fig. 2) . Taken together, these results suggest that the reversible occupation of alpha-1 adrenoceptors by dexmedetomidine may provide them with partial protection form irreversible blockade by phenoxybenzamine in a dose-dependent manner. The decreasing order of the magnitude of the reversible blockade of alpha-1 adrenoceptors observed in the current study was as follows: phentolamine, 10 -6 M dexmedetomidine, 3 × 10 -7 M dexmedetomidine. Furthermore, dexmedetomidine attenuated phenylephrine-induced contraction, whereas it did not significantly alter contraction induced by the 5-hyroxytryptamine receptor agonist 5-hydroxytryptamine, suggesting that dexmedetomidinemediated inhibition appears to be associated with alpha-1 adrenoceptor blockade. In addition, dexmedetomidine-induced contraction is mediated by the alpha-2B and alpha-1 adrenoceptors in mesenteric arteries [19] . In agreement with a previous report, high-dose dexmedetomidine-induced contraction was attenuated by prazosin at a concentration of 3 x 10 -9 M, which corresponds to the concentration of prazosin necessary to inhibit alpha-1 adrenoceptors [16, 19] . Dexmedetomidine shows a low affinity for the alpha-1 adrenoceptor and is a partial agonist of the human alpha-1B adrenoceptor [9, 10] . Taking previous findings into consideration, the putative mechanism associated with the dexmedetomidine-mediated inhibition of phenylephrine-induced contraction is as follows [9, 10] . Although dexmedetomidine is a highly selective alpha-2 adrenoceptor agonist (α2/α1 selectivity ratio: 1620) compared with other alpha-2 adrenoceptor agonists, at high doses, dexmedetomidine may occupy a small proportion of alpha-1 adrenoceptors [2] . Thus, because of the competitive inhibition of alpha-1 adrenoceptors by phenylephrine and high-dose dexmedetomidine, the number of unoccupied alpha-1 adrenoceptors available for phenylephrine binding may decrease, leading to dexmedetomidine-mediated inhibition of phenylephrine-induced contraction. . HUVECs were treated with phenylephrine (10 -8 M) alone for 1 min; or pretreated with dexmedetomidine (3 × 10 -7 M) for 10 min, followed by treatment with 10 -8 M phenylephrine for 1 min; or pretreated with 10 -6 M rauwolscine for 1 h, followed by post-treatment with dexmedetomidine (3 × 10 -7 M) for 10 min and subsequent treatment with 10 -8 M phenylephrine for 1 min. The phosphorylation of eNOS was investigated as described in the Methods. The data are shown as the mean ± SD. N indicates the number of independent experiments. *P < 0.001 versus the control. †P < 0.001 versus phenylephrine alone. #P < 0.001 versus dexmedetomidine plus phenylephrine. p-eNOS: phosphorylated eNOS. t-eNOS: total eNOS.
